Neuronetics, Inc. (STIM)

Market Cap	273.10M
Revenue (ttm)	111.11M
Net Income (ttm)	-48.80M
Shares Out	66.12M
EPS (ttm)	-1.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,212,443
Open	4.000
Previous Close	4.005
Day's Range	3.919 - 4.310
52-Week Range	0.520 - 5.920
Beta	1.78
Analysts	Buy
Price Target	5.67 (+37.29%)
Earnings Date	Aug 5, 2025

About STIM

Neuronetics, Inc. engages in providing in office treatments for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company s...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jun 28, 2018
• Employees: 716
• Stock Exchange: NASDAQ
• Ticker Symbol: STIM
• Website: https://neurostar.com

Financial Performance

In 2024, Neuronetics's revenue was $74.89 million, an increase of 4.96% compared to the previous year's $71.35 million. Losses were -$43.71 million, 44.8% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for STIM stock is "Buy." The 12-month stock price target is $5.67, which is an increase of 37.29% from the latest price.

Price Target

$5.67

(37.29% upside)

Analyst Consensus: Buy